DK1257281T3 - Nukleosidanaloger med carboxamidin-modificeret monocyklisk base - Google Patents

Nukleosidanaloger med carboxamidin-modificeret monocyklisk base

Info

Publication number: DK1257281T3
Authority: DK; Denmark
Prior art keywords: carboxamidine; nucleoside analogs; monocyclic base; modified; modified monocyclic
Prior art date: 2000-02-15

Application number

DK01920996T

Other languages

Danish (da)

English (en)

Inventor

Robert Tam

Kanda Ramasamy

Zhi Hong

Johnson Lau

Original Assignee

Valeant Pharmaceuticals North

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2001-02-15

Publication date

2008-01-14

2001-02-15 Application filed by Valeant Pharmaceuticals North filed Critical Valeant Pharmaceuticals North

2008-01-14 Application granted granted Critical

2008-01-14 Publication of DK1257281T3 publication Critical patent/DK1257281T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

DK01920996T 2000-02-15 2001-02-15 Nukleosidanaloger med carboxamidin-modificeret monocyklisk base DK1257281T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US18267600P	2000-02-15	2000-02-15
US09/595,365 US6455508B1 (en)	2000-02-15	2000-10-05	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
PCT/US2001/040148 WO2001060379A1 (en)	2000-02-15	2001-02-15	Nucleoside analogs with carboxamidine modified monocyclic base

Publications (1)

Publication Number	Publication Date
DK1257281T3 true DK1257281T3 (da)	2008-01-14

Family

ID=26878297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01920996T DK1257281T3 (da)	2000-02-15	2001-02-15	Nukleosidanaloger med carboxamidin-modificeret monocyklisk base

Country Status (29)

Country	Link
US (1)	US6455508B1 (zh)
EP (3)	EP1257281B8 (zh)
JP (3)	JP2004510691A (zh)
KR (2)	KR20030005190A (zh)
CN (2)	CN1420779A (zh)
AT (1)	ATE377422T1 (zh)
AU (2)	AU783142B2 (zh)
BR (2)	BR0108402A (zh)
CA (2)	CA2395854A1 (zh)
CY (1)	CY1107103T1 (zh)
CZ (2)	CZ20022799A3 (zh)
DE (1)	DE60131250T8 (zh)
DK (1)	DK1257281T3 (zh)
ES (2)	ES2528429T3 (zh)
HK (1)	HK1051149A1 (zh)
HR (2)	HRP20020583A2 (zh)
HU (2)	HU229480B1 (zh)
IL (3)	IL150990A0 (zh)
MX (2)	MXPA02007931A (zh)
NO (2)	NO20023852L (zh)
NZ (2)	NZ521390A (zh)
PL (2)	PL365239A1 (zh)
PT (1)	PT1257281E (zh)
RS (1)	RS20090086A (zh)
RU (2)	RU2259831C2 (zh)
SI (2)	SI21077A (zh)
SK (2)	SK287765B6 (zh)
WO (2)	WO2001060381A1 (zh)
YU (1)	YU61502A (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6831069B2 (en) *	1999-08-27	2004-12-14	Ribapharm Inc.	Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7056895B2 (en) *	2000-02-15	2006-06-06	Valeant Pharmaceuticals International	Tirazole nucleoside analogs and methods for using same
US7638496B2 (en) *	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) *	2000-05-26	2008-03-07	이데닉스(케이만)리미티드	플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
GEP20053601B (en)	2001-01-22	2005-08-10	Merck & Co Inc	Nucleoside Derivatives as Inhibitors of RNA-Dependent RNA Viral Polymerase
WO2003037908A1 (en) *	2001-10-31	2003-05-08	Ribapharm Inc.	Antiviral combination therapy and compositions
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh)	2002-06-28	2008-05-07	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7662798B2 (en)	2002-06-28	2010-02-16	Idenix Pharmaceuticals, Inc.	2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7824851B2 (en)	2002-11-15	2010-11-02	Idenix Pharmaceuticals, Inc.	2′-branched nucleosides and Flaviviridae mutation
EP1585529A4 (en)	2002-12-12	2008-05-28	Idenix Cayman Ltd	PROCESS FOR PREPARING 2'-BRANCHED NUCLEOSIDES
US20050049204A1 (en) *	2003-03-28	2005-03-03	Otto Michael J.	Compounds for the treatment of flaviviridae infections
US20040197287A1 (en) *	2003-04-04	2004-10-07	The Procter & Gamble Company	Personal care composition containing an antidandruff component and a nonionic surfactant
US20040197292A1 (en) *	2003-04-04	2004-10-07	The Procter & Gamble Company	Personal care composition containing an antidandruff component and a nonionic surfactant
US20040202636A1 (en) *	2003-04-11	2004-10-14	Kaczvinsky Joseph Robert	Personal care composition containing an antidandruff component and a nonionic surfactant
US6930093B2 (en) *	2003-07-10	2005-08-16	Valeant Research & Development	Use of ribofuranose derivatives against inflammatory bowel diseases
US20050009848A1 (en) *	2003-07-10	2005-01-13	Icn Pharmaceuticals Switzerland Ltd.	Use of antivirals against inflammatory bowel diseases
WO2005018330A1 (en) *	2003-08-18	2005-03-03	Pharmasset, Inc.	Dosing regimen for flaviviridae therapy
US20050095218A1 (en) *	2003-10-29	2005-05-05	The Procter & Gamble Company	Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
CA2568379A1 (en)	2004-06-15	2005-12-29	Merck & Co., Inc.	C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
JP4705164B2 (ja)	2005-05-02	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
TWI387603B (zh)	2005-07-20	2013-03-01	Merck Sharp & Dohme	Ｈｃｖｎｓ３蛋白酶抑制劑
EP1913016B1 (en)	2005-08-01	2013-01-16	Merck Sharp & Dohme Corp.	Macrocyclic peptides as hcv ns3 protease inhibitors
US7781576B2 (en)	2005-12-23	2010-08-24	Idenix Pharmaceuticals, Inc.	Process for preparing a synthetic intermediate for preparation of branched nucleosides
AU2006342447B2 (en) *	2005-12-28	2013-06-20	Translational Therapeutics, Inc	Translational dysfunction based therapeutics
US8497292B2 (en)	2005-12-28	2013-07-30	Translational Therapeutics, Inc.	Translational dysfunction based therapeutics
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
US7842672B2 (en)	2006-07-07	2010-11-30	Gilead Sciences, Inc.	Phosphonate inhibitors of HCV
JP5345941B2 (ja)	2006-10-24	2013-11-20	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
AU2007309544B2 (en)	2006-10-24	2012-05-31	Msd Italia S.R.L.	HCV NS3 protease inhibitors
AU2007309546A1 (en)	2006-10-24	2008-05-02	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	HCV NS3 protease inhibitors
BRPI0718161A2 (pt)	2006-10-27	2013-11-26	Merck & Co Inc	Composto, composição farmacêutica, e, uso do composto.
JP5352464B2 (ja)	2006-10-27	2013-11-27	メルク・シャープ・アンド・ドーム・コーポレーション	Ｈｃｖｎｓ３プロテアーゼ阻害剤
WO2008075103A1 (en)	2006-12-20	2008-06-26	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Antiviral indoles
GB0625345D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
GB0625349D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
RU2466729C2 (ru) *	2006-12-28	2012-11-20	Айденикс Фармасьютикалз, Инк.	Соединения и фармацевтические композиции для лечения вирусных инфекций
JP2010533698A (ja)	2007-07-17	2010-10-28	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	Ｃ型肝炎感染症の治療のための大環状インドール誘導体
CN101754974B (zh)	2007-07-19	2016-02-03	Msd意大利有限公司	作为抗病毒剂的大环化合物
US8461107B2 (en)	2008-04-28	2013-06-11	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
EA019327B1 (ru)	2008-07-22	2014-02-28	Мерк Шарп Энд Домэ Корп.	Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
WO2010082050A1 (en)	2009-01-16	2010-07-22	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en)	2009-01-20	2009-03-04	Angeletti P Ist Richerche Bio	Antiviral agents
WO2011014487A1 (en)	2009-07-30	2011-02-03	Merck Sharp & Dohme Corp.	Hepatitis c virus ns3 protease inhibitors
WO2013074386A2 (en)	2011-11-15	2013-05-23	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
WO2013106344A1 (en)	2012-01-12	2013-07-18	Ligand Pharmaceuticals, Inc.	2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
CN102978264B (zh) *	2012-11-14	2014-12-10	广东肇庆星湖生物科技股份有限公司	一种他立韦林的制备方法
WO2014121418A1 (en)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN106061984A (zh)	2014-02-13	2016-10-26	配体药物公司	前药化合物及其用途
EP3164136A4 (en)	2014-07-02	2018-04-04	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
KR102630013B1 (ko)	2015-08-06	2024-01-25	키메릭스 인크.	항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체
US11111264B2 (en)	2017-09-21	2021-09-07	Chimerix, Inc.	Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
JP2021509907A (ja)	2018-01-09	2021-04-08	リガンド・ファーマシューティカルズ・インコーポレイテッド	アセタール化合物およびその治療的使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3984396A (en)	1971-06-01	1976-10-05	Icn Pharmaceuticals, Inc.	1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3798209A (en)	1971-06-01	1974-03-19	Icn Pharmaceuticals	1,2,4-triazole nucleosides
US3991078A (en)	1971-06-01	1976-11-09	Icn Pharmaceuticals, Inc.	N-substituted 1,2,4-triazoles
USRE29835E (en)	1971-06-01	1978-11-14	Icn Pharmaceuticals	1,2,4-Triazole nucleosides
US3962211A (en) *	1975-01-13	1976-06-08	The University Of Utah	7-substituted nucleoside compounds
US4093624A (en)	1977-01-31	1978-06-06	Icn Pharmaceuticals, Inc.	1,2,4-Thiadiazolidine-3,5-dione
JPS6426593A (en)	1987-07-21	1989-01-27	Asahi Glass Co Ltd	Nucleoside derivative
US4892865A (en) *	1987-12-01	1990-01-09	The Regents Of The University Of Michigan	Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
CA2246162C (en) *	1996-01-23	2000-04-04	Icn Pharmaceuticals, Inc.	Modulation of th1/th2 cytokine expression by ribavirin.rtm. and ribavirin.rtm. analogs in activated t-lymphocytes
BR9712527A (pt) *	1996-10-16	2000-03-08	Icn Pharmaceuticals	L-nucleosìdeos monocìclicos, análogos e seus empregos
RU2002103501A (ru) *	1999-08-27	2003-09-10	Ай-Си-Эн Фармасьютикалз, Инк. (Us)	Пирроло[2,3-d] пиримидиновые нуклеозидные аналоги

2000
- 2000-10-05 US US09/595,365 patent/US6455508B1/en not_active Expired - Lifetime
2001
- 2001-02-15 ES ES07107588.1T patent/ES2528429T3/es not_active Expired - Lifetime
- 2001-02-15 EP EP01920996A patent/EP1257281B8/en not_active Expired - Lifetime
- 2001-02-15 SI SI200120011A patent/SI21077A/sl not_active IP Right Cessation
- 2001-02-15 SI SI200120010A patent/SI21076A/sl not_active IP Right Cessation
- 2001-02-15 WO PCT/US2001/005172 patent/WO2001060381A1/en active Search and Examination
- 2001-02-15 YU YU61502A patent/YU61502A/sh unknown
- 2001-02-15 WO PCT/US2001/040148 patent/WO2001060379A1/en active Search and Examination
- 2001-02-15 NZ NZ521390A patent/NZ521390A/en unknown
- 2001-02-15 SK SK1149-2002A patent/SK287765B6/sk not_active IP Right Cessation
- 2001-02-15 PT PT01920996T patent/PT1257281E/pt unknown
- 2001-02-15 AU AU47988/01A patent/AU783142B2/en not_active Ceased
- 2001-02-15 DK DK01920996T patent/DK1257281T3/da active
- 2001-02-15 HU HU0300027A patent/HU229480B1/hu unknown
- 2001-02-15 MX MXPA02007931A patent/MXPA02007931A/es active IP Right Grant
- 2001-02-15 SK SK1157-2002A patent/SK11572002A3/sk unknown
- 2001-02-15 PL PL01365239A patent/PL365239A1/xx unknown
- 2001-02-15 CA CA002395854A patent/CA2395854A1/en not_active Abandoned
- 2001-02-15 JP JP2001559477A patent/JP2004510691A/ja active Pending
- 2001-02-15 IL IL15099001A patent/IL150990A0/xx unknown
- 2001-02-15 CZ CZ20022799A patent/CZ20022799A3/cs unknown
- 2001-02-15 JP JP2001559475A patent/JP4975930B2/ja not_active Expired - Fee Related
- 2001-02-15 RS RSP-2009/0086A patent/RS20090086A/sr unknown
- 2001-02-15 MX MXPA02007932A patent/MXPA02007932A/es unknown
- 2001-02-15 BR BR0108402-0A patent/BR0108402A/pt not_active Application Discontinuation
- 2001-02-15 EP EP07107588.1A patent/EP1813278B9/en not_active Expired - Lifetime
- 2001-02-15 PL PL357945A patent/PL200140B1/pl unknown
- 2001-02-15 RU RU2002120922/15A patent/RU2259831C2/ru active
- 2001-02-15 CN CN01805036A patent/CN1420779A/zh active Pending
- 2001-02-15 KR KR1020027010593A patent/KR20030005190A/ko not_active Application Discontinuation
- 2001-02-15 NZ NZ52087701A patent/NZ520877A/xx not_active IP Right Cessation
- 2001-02-15 AU AU38450/01A patent/AU3845001A/en not_active Abandoned
- 2001-02-15 IL IL15055501A patent/IL150555A0/xx unknown
- 2001-02-15 CA CA2399208A patent/CA2399208C/en not_active Expired - Fee Related
- 2001-02-15 CZ CZ20022798A patent/CZ302327B6/cs not_active IP Right Cessation
- 2001-02-15 EP EP01910892A patent/EP1278528A4/en not_active Withdrawn
- 2001-02-15 HU HU0300912A patent/HUP0300912A2/hu unknown
- 2001-02-15 RU RU2002120483/14A patent/RU2002120483A/ru not_active Application Discontinuation
- 2001-02-15 CN CNB018077455A patent/CN1268335C/zh not_active Expired - Fee Related
- 2001-02-15 ES ES01920996T patent/ES2295148T3/es not_active Expired - Lifetime
- 2001-02-15 BR BR0108401-1A patent/BR0108401A/pt not_active IP Right Cessation
- 2001-02-15 KR KR1020027010417A patent/KR100811927B1/ko not_active IP Right Cessation
- 2001-02-15 DE DE60131250T patent/DE60131250T8/de active Active
- 2001-02-15 AT AT01920996T patent/ATE377422T1/de active
2002
- 2002-07-08 HR HR20020583A patent/HRP20020583A2/xx not_active Application Discontinuation
- 2002-07-30 IL IL150990A patent/IL150990A/en not_active IP Right Cessation
- 2002-08-07 HR HR20020657A patent/HRP20020657A2/hr not_active Application Discontinuation
- 2002-08-14 NO NO20023852A patent/NO20023852L/no not_active Application Discontinuation
- 2002-08-14 NO NO20023855A patent/NO329927B1/no not_active IP Right Cessation
2003
- 2003-05-19 HK HK03103531A patent/HK1051149A1/xx not_active IP Right Cessation
2007
- 2007-12-19 CY CY20071101614T patent/CY1107103T1/el unknown
2009
- 2009-01-29 JP JP2009018382A patent/JP5253204B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE377422T1 (de)	2007-11-15
JP4975930B2 (ja)	2012-07-11
NO329927B1 (no)	2011-01-24
AU3845001A (en)	2001-08-27
KR100811927B1 (ko)	2008-03-10
YU61502A (sh)	2006-03-03
NO20023852D0 (no)	2002-08-14
ES2295148T3 (es)	2008-04-16
US6455508B1 (en)	2002-09-24
EP1813278B1 (en)	2014-10-29
SK11572002A3 (sk)	2003-02-04
AU4798801A (en)	2001-08-27
NZ520877A (en)	2004-12-24
MXPA02007932A (es)	2004-10-15
CY1107103T1 (el)	2012-10-24
RU2259831C2 (ru)	2005-09-10
PT1257281E (pt)	2007-12-11
SK11492002A3 (sk)	2003-02-04
HRP20020583A2 (en)	2005-10-31
JP2009102406A (ja)	2009-05-14
PL200140B1 (pl)	2008-12-31
EP1257281A4 (en)	2003-03-19
PL365239A1 (en)	2004-12-27
HK1051149A1 (en)	2003-07-25
HRP20020657A2 (en)	2005-10-31
MXPA02007931A (es)	2004-10-15
EP1278528A4 (en)	2003-03-19
CA2399208C (en)	2010-04-13
CZ302327B6 (cs)	2011-03-16
JP2004510691A (ja)	2004-04-08
KR20030005190A (ko)	2003-01-17
WO2001060381B1 (en)	2001-11-01
CN1438891A (zh)	2003-08-27
CN1268335C (zh)	2006-08-09
NO20023855D0 (no)	2002-08-14
AU783142B2 (en)	2005-09-29
PL357945A1 (en)	2004-08-09
RS20090086A (en)	2010-06-30
EP1257281A1 (en)	2002-11-20
KR20030032917A (ko)	2003-04-26
EP1813278B9 (en)	2015-04-01
CN1420779A (zh)	2003-05-28
NO20023852L (no)	2002-10-09
DE60131250T8 (de)	2009-01-15
WO2001060381A1 (en)	2001-08-23
SK287765B6 (sk)	2011-09-05
JP5253204B2 (ja)	2013-07-31
EP1278528A1 (en)	2003-01-29
EP1257281B8 (en)	2008-01-23
SI21076A (sl)	2003-06-30
CA2395854A1 (en)	2001-08-23
IL150990A (en)	2009-05-04
RU2002120922A (ru)	2004-01-27
CZ20022798A3 (cs)	2003-03-12
CA2399208A1 (en)	2001-08-23
HU229480B1 (en)	2014-01-28
IL150990A0 (en)	2003-02-12
HUP0300027A3 (en)	2003-09-29
CZ20022799A3 (cs)	2003-09-17
DE60131250T2 (de)	2008-08-28
ES2528429T9 (es)	2015-05-07
HUP0300912A2 (hu)	2003-08-28
BR0108402A (pt)	2003-03-11
WO2001060379A1 (en)	2001-08-23
EP1257281B1 (en)	2007-11-07
HUP0300027A2 (en)	2003-05-28
NZ521390A (en)	2004-05-28
EP1813278A1 (en)	2007-08-01
IL150555A0 (en)	2003-02-12
ES2528429T3 (es)	2015-02-09
BR0108401A (pt)	2004-01-06
DE60131250D1 (de)	2007-12-20
RU2002120483A (ru)	2004-01-27
JP2004509061A (ja)	2004-03-25
NO20023855L (no)	2002-10-08
SI21077A (sl)	2003-06-30

Publication	Publication Date	Title
DK1257281T3 (da)	2008-01-14	Nukleosidanaloger med carboxamidin-modificeret monocyklisk base
MY128463A (en)	2007-02-28	4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
EE02995B1 (et)	1997-06-16	1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
WO2003051306A3 (en)	2003-12-18	N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
BG108439A (en)	2005-03-31	4'-substituted nucleosides
NZ609146A (en)	2014-08-29	Modified 4’-nucleosides as antiviral agents
NZ610715A (en)	2014-07-25	Antiviral compounds and methods
IL152934A (en)	2010-12-30	Use of a nucleoside in the manufacture of a medicament for treating heapatitis c virus
JP2004509061A5 (zh)	2006-01-05
ZA200904031B (en)	2010-04-28	Chemical compounds
EA200701869A1 (ru)	2008-02-28	Пептидомиметические ингибиторы протеазы
AP1771A (en)	2007-08-23	3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
JO2403B1 (en)	2007-06-17	Nickeloside derivatives antiviral
DE60215157D1 (de)	2006-11-16	Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
DK1115420T3 (da)	2002-11-04	Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
MX9202634A (es)	1994-01-31	Uso de analogos de nucleosido de 1,3-oxatiolano en el tratamiento de hepatitis b.
ATE270886T1 (de)	2004-07-15	Antivirale therapie